Protagonist Therapeutics (PTGX) PT Raised to $119 at Barclays following Icotyde approval

March 18, 2026 12:17 PM

Barclays analyst Etzer Darout raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $119.00 (from $113.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found